In crowded field of psychedelic startups, Filament CEO makes case for ‘natural’ drugs ...Middle East

Sentinel-Tribune - News
In crowded field of psychedelic startups, Filament CEO makes case for ‘natural’ drugs
A recent boom in psychedelic research has given way to a bumper crop of startups seeking to harness the potential of mind-altering drugs for treating depression, addiction and other conditions. In this crowded field, Vancouver-based Filament Health has a unique approach: extracting drugs like psilocybin and mescaline from natural sources, including mushrooms and cacti, rather than synthesizing the ingredients in a laboratory. Filament is studying its mushroom-based psilocybin as a treatment for opioid and stimulant use disorder. And more than a dozen other companies and academic centers are using the company’s drugs in trials of depression, chronic pain and other disorders. Filament CEO Benj

Hence then, the article about in crowded field of psychedelic startups filament ceo makes case for natural drugs was published today ( ) and is available on Sentinel-Tribune ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( In crowded field of psychedelic startups, Filament CEO makes case for ‘natural’ drugs )

Apple Storegoogle play

Last updated :

Also on site :